Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

← catalyst calendar

NCT05760313 · results posted

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →. With Ironwood Pharmaceuticals, Inc..

Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
19actual
Sites
38
Countries
Bulgaria, Croatia, Germany +4

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2023-04-27actualWhen the study began enrolling
Primary completion2025-06-09actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-06-09actualThe whole study's end, after follow-up
First posted2023-03-08actualWhen this record first appeared on the registry
Results posted2026-01-06actualWhen the sponsor posted results to the registry
Record updated2026-01-06actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Functional Constipation

Interventions

  • Drug: Linaclotide — also filed as Linzess
  • Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF
Change From Baseline in Overall Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) During the Study Intervention Period
measured Baseline to Week 4
Change From Baseline in Stool Consistency (Bristol Stool Form Scale) During the Study Intervention Period
measured Baseline to Week 4
Change From Baseline in Straining During the Study Intervention Period
measured Baseline to Week 4
Number of Participants With Adverse Events (AEs)
measured Up to Week 5

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2024-11-25 · 3.9 MB · Prot_000.pdf
Statistical Analysis Planposted 2023-05-17 · 452 KB · SAP_001.pdf

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed